NCT04674189

A Study to Evaluate the Safety and Immunogenicity of Vaccine CVnCoV in Healthy Adults in Germany for COVID-19

COVID-19: A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Clinical Study Evaluating the Safety and Immunogenicity of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adult Health Care Workers in Mainz (Germany)

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 2,357 (actual)
• Sponsor: CureVac · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

This study aims to evaluate the safety (in all participants) and reactogenicity (in a subset of participants) of CVnCoV administered as a 2-dose schedule to adult participants 18 years of age or older. The study also aims to assess antibody responses to the receptor-binding domain (RBD) of spike (S) protein of SARS-CoV-2 after 1 and 2 doses of CVnCoV in adults 18 years of age or older included in a subset of participants.

Conditions

• Coronavirus
• Covid19
• SARS-CoV-2
• Severe Acute Respiratory Syndrome

Interventions

Type	Name	Description
BIOLOGICAL	CVnCoV Vaccine	Intramuscular injection
DRUG	Placebo	Intramuscular injection

Timeline

• Start date: 2020-12-23
• Primary completion: 2022-06-08
• Completion: 2022-06-08
• First posted: 2020-12-19
• Last updated: 2023-10-06
• Results posted: 2023-10-06

Locations

1 site across 1 country: Germany